Last reviewed · How we verify

NCT05862038

Biomarkers in Pulsed Field Ablation Versus Cryoballoon Ablation

Status unknown Last updated 19 May 2023
What this trial tests

trial in Atrial Fibrillation in 100 participants. Status unknown.

Timeline
10 February 2023
Primary endpoint
10 July 2024
10 September 2024

Quick facts

Lead sponsorAna Jordan
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date10 February 2023
Primary completion10 July 2024
Estimated completion10 September 2024
Sites1 location across Croatia

Conditions studied

Sponsor

Ana Jordan

Who can join

Adults 18 to 75, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study will include consecutive patients undergoing pulsed field ablation (PFA) or cryoballoon (CBA) ablation. Tissue injury and inflammation markers will be measured before and after the procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05862038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing